Journal of lung cancer最新文献

{"title":"Palliative Chemotherapy for Patients with Pulmonary Pleomorphic Carcinoma: A Retrospective Single-institutional Study","authors":"S. Minami, Suguru Yamamoto, K. Komuta","doi":"10.4172/2576-1447.1000S1-008","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-008","url":null,"abstract":"Objective: Pulmonary pleomorphic carcinoma (PPC) is considered to be highly resistant to conventional standard chemotherapy for non-small cell lung cancer and associated with poor prognosis. Because of its histological rarity, the efficacy of palliative chemotherapy is not well-known. This study aimed to clarify the efficacy of palliative chemotherapy for this rare type of aggressive tumor. \u0000Method: We retrospectively reviewed our medical records. We collected data on patients who had been histologically diagnosed of PPC and received palliative chemotherapy between June 2007 and December 2014 at Osaka Police Hospital. \u0000Results: Among a total of 1461 primary lung cancers, 29 patients (2.0%) were diagnosed with PPC. Seventeen patients, including 15 males and 3 females, received palliative chemotherapy. Patients had the median age of 67 years (range, 43-80 years) and included twelve stage IV, four stage IIIB and one post-surgical recurrent diseases. Twelve patients received platinum-based regimen, while five were treated with monotherapy. The most frequent regimen in the first-line chemotherapy was combination of carboplatin plus paclitaxel. Response was found in a patient who had been treated with a triple combination of carboplatin, paclitaxel plus bevacizumab. The response rate (RR), disease control rate (DCR), median progression-free survival (PFS), median overall survival (OS) and 1- year survival rate of the first-line chemotherapy were 5.9% (95% confidence interval; 0.1-28.7%), 35.3% (14.2-61.7%), 45 days (35-115 days), 179 days (64-303 days) and 19.0% (4.7-40.6%), respectively. Among 15 regimens per 9 patients in the second- and further-line settings, none experienced response. The RR, DCR, median PFS, median OS and 1-year survival rate of the second-line chemotherapy (n=9) were 0% (0-28.3%), 33.3% (7.5-70.1%), 77 days (3-142 days), 144 days (5-331 days) and 11.1% (0.6-38.8%), respectively. \u0000Conclusion: Palliative chemotherapy was futile for advanced PPC. Further investigation of a new approach to this aggressive tumor is required.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2016-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Positron Emission Tomography derived Parameters as Predictive Factors andSurvival in Non-small Cell Lung Cancer Patients","authors":"M. H. Khan, Khan Mi, L. Pettit, R. Amir, A. Chetiyawardana","doi":"10.4172/2576-1447.1000S1-009","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-009","url":null,"abstract":"Background: CT-PET (Computed Tomography-Positron Emission Tomography) provides additional information regarding tumour characteristics, aggressive tumour behaviour and serves as a prognostic indicator. Methods: Thirty one patients with NSCLC were retrospectively reviewed. PET parameters were calculated including maximum and mean Standardised Uptake Value (SUV), Metabolic Tumour Volume (MTV) and Total Lesion Glycolysis (TLG=MTV× SUVmean). The correlation between each parameter was investigated using Pearson's correlation tests. The tumour doubling time (DT) was calculated from pre-treatment and treatment planning CT scans. The DT was divided into 2 groups: A-rapid (DT 180 d) for survival calculation. Results: The mean age at diagnosis was 75 (55-87) years, 22 (66.7%) were male and 9 (27.3%) were female. The majority of patients had stage I and II (93.5%) disease. The correlation between DT to TLG and SUVmean was significant with Pearson's correlation of -0.363 (p-value of 0.045 on 2 tailed) and -0.399 (p-value of 0.024 on 2 tailed) respectively. DT correlation to SUVmax and MTV was not significant on Pearson’s correlation of -0.337 (p- value of 0.064 on 2 tailed test) and -0.309 (p-value of 0.091 on 2 tailed) respectively. The 2 year overall survival was 45.2% and median survival was 503 days for the whole group. The median survival was 468 days in group A-rapid and 503 days in B-slow group patients. There was no statistically significant difference between the groups (Log Rank Mantle Cox with p-value=0.681). Conclusions: This study compares the relationship of PET parameters (SUV, MTV and TLG) and DT and prediction of prognostication. Although the clinical significance can be far reaching at this stage, TLG and SUVmax are promising predictive factors for doubling time in NSCLC. Larger studies are needed to support the findings.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atelectasis of Lung as a First Sign of Lung Cancer: A Case Report","authors":"Utsav Pokharel, Sushmita Shrestha, P. Neupane","doi":"10.4172/2576-1447.1000S1-006","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-006","url":null,"abstract":"Atelectasis is a common finding in chest x rays in inpatient settings. While atelectasis that clears with regular respiratory toiling may signify a benign etiology, it could be the first sign of airway malignancy. Lung cancer is common and smoking is the main risk factor for primary lung cancer. Here we present the story of a 77 years old female in whom atelectasis was the first sign of lung cancer. In patients with appropriate risk factors, atelectasis should be pursued further to rule out underlying lung cancer.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the Amount of Malignant Pleural Effusion affect the Survival in Patientswith Non-small Cell Lung Cancer?","authors":"S. Nakamura, T. Fukui, K. Kawaguchi, T. Okasaka, K. Fukumoto, T. Hase, Y. Hasegawa, A. Hirakawa, K. Yokoi","doi":"10.4172/2576-1447.1000S1-007","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-007","url":null,"abstract":"Objective: Malignant pleural effusion (MPE) in patients with non-small cell lung cancer (NSCLC) is uniformly classified as M1a/stage IV disease in the current TNM classification, irrespective of its amount, and it is considered to be an incurable disease condition. Although a small amount of MPE had been reported to be an early phase of pleural carcinomatosis, its clinical relevance has rarely been studied. In this study, we examined the influence of the amount of MPE on the survival of patients with NSCLC. Materials and Methods: Sixty patients with pleural carcinomatosis referred to our institution between 2005 and 2012 were enrolled. The patients were classified into three groups according to the amount of MPE on chest computed tomography (CT): E0, no MPE (n=21); E1, a small amount of MPE (<1.0 cm thick on CT, n=19); and E2, a large amount of MPE (≥1.0 cm thick on CT, n=20). The association between the clinicopathological factors, including the amount of MPE, and the survival were investigated using univariate and multivariate analyses. Results: The patients with E2 had significantly shorter survivals than the E0 and E1 groups (median survival of 16, 31, and 20 months, respectively; log-rank test, P<0.01), while there was no significant difference between the E0 and E1 groups. In the multivariate analysis, histology, EGFR gene mutation status, and the amount of MPE remained significant prognostic factors. Conclusion: The amount of MPE in NSCLC might be an important prognostic factor and affect patient survival. In the TNM classification, the amount of MPE should be considered for inclusion in the definition of T descriptor or stage grouping.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2016-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer and Blood Vessels: A Complex Relationship.","authors":"F. Pezzella","doi":"10.4172/2576-1447.1000S1-002","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-002","url":null,"abstract":"The relationship between vessels and cancer has been the subject of many studies. In 1787 was formulated the idea that tumors always induced growth of new vessels, a phenomenon called \"angiogenesis\". The growth of new capillaries into tumor implants was formally described in animal models only in 1939 but during the same years was also published that only pre-existing vessels could be identified inside some neoplastic lesions. During the 1970s, Folkman started to systematically investigate the role of newly formed vessels in cancer and the angiogenesis theory, i.e. the complete reliance of cancers on new vessels in order to grow, become predominant. Eventually recent work has demonstrated that some tumors can truly grow without inducing angiogenesis as the neoplastic cells exploit the preexisting vessels by co-opting them.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2016-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smoking Cessation in Lung Cancer.","authors":"Ş. Akçay, Balam Er Dedekargınoglu","doi":"10.4172/2576-1447.1000S1-004","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-004","url":null,"abstract":"The greatest risk factor for lung cancer is smoking. Smoking addiction is one of the challenging problems that should be solved in lung cancer patients. Including lung cancer, in cancer patients, quitting smoking has several benefits. However, implementation of smoking cessation clinics in oncology practices is inadequate and many lung cancer patients still smoke despite cancer diagnosis. Multidisciplinary lung cancer treatment programs offer effective smoking cessation services. This article reviews the best practice recommendations of tobacco addiction treatment for oncology patients in multidisciplinary practice.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":"1-3"},"PeriodicalIF":0.0,"publicationDate":"2016-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of Next-generation Sequencing in a Case of Metastatic Breast Carcinoma with Pulmonary Lesions","authors":"N. Kotecki, E. Surmei-Pintilie, O. Abramovici, J. Bonneterre, É. Dansin","doi":"10.4172/2576-1447.1000S1-003","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-003","url":null,"abstract":"Next-Generation Sequencing (NGS) provide specific cancer-related gene-sequence information which can be helpful for diagnosis and clinical decision. Here we describe the case of a patient diagnosed with HER2 positive metastatic breast cancer and successive pulmonary lesions. Despite large immunohistochemical assays. It was not possible to distinguish on first thoracic specimen between primary lung adenocarcinoma and metastasis from breast carcinoma. NGS analysis on second thoracic sample detected somatic mutations in PiK3CA and TP53 genes. This mutation profile was identical to the previously resected adenocarcinoma. NGS contribute to diagnose metachronous primary lung carcinoma and to propose a thoracic treatment in addition to systemic management of metastatic breast carcinoma. Our case report emphasizes the usefulness of NGS to guide diagnosis and treatment in the objective of precision medicine.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"To Stent or not to Stent and if Stented When to Remove it? Glimpse ofInterventional Pulmonology Conundrums with an Illustrative Series","authors":"A. Agrawal, A. Agarwal, Susan Kagebein, Lenard Persaud, N. Meena","doi":"10.4172/2576-1447.1000S1-005","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-005","url":null,"abstract":"The role of airway stenting to alleviate airway obstruction was first described in the late 1800s. Airway stents have since been used for fistulas in the bronchial tree as well. Airway stenting has the ability to rapidly achieve the shortterm goals. However, the long-term side effects of a foreign body in the airway should temper the enthusiasm for indiscriminate use. We present this series to highlight the need for proper assessment of need before the placement of the stent, followed by constant vigilance after the placement.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Prospective Study to Evaluate Clinical Radiation Induced Pneumonitis in Lung Cancer Patients and its Dose Response Relationship with Radiotherapy","authors":"Sayanna Das, S. Misra, A. Munshi, S. Rathod, N. Pur, Are, T. eep, On, J. Agarwal","doi":"10.4172/2576-1447.1000S1-001","DOIUrl":"https://doi.org/10.4172/2576-1447.1000S1-001","url":null,"abstract":"Purpose: This study was initiated to evaluate incidence, grade and dosimetric correlation of Clinical Radiation Induced Pneumonitis (RIP) (≥ grade 2) in lung cancer patients undergoing radical radiotherapy. \u0000Methods and Materials: From August, 2012 to November, 2013, 85 lung cancer patients received curative 3D CRT. On follow up 14 patients developed symptomatic pneumonitis (≥ Grade 2 as per RTOG Toxicity criteria). They underwent CT thorax/PET-CT at 3 monthly follow-up which were co-registered with planning CT images. Changes in lung density were graded as patchy, discrete and solid consolidation and contoured. Isodose surface enveloping these contours and mean doses received were noted. \u0000Result: At a median follow up of 12.5 months, incidence of clinical ≥Grade 2 RIP was 16.5%. Inclusion of mediastinum in the target volume and higher stage of disease were found to be indicators of increased risk of ≥Grade 2 RIP. Lung volumes showing patchy/discrete consolidation decreased from 3rd to 6th month and then plateaued while solid consolidation appeared at 6 months, increased at 9 months but then decreased at 12 months. Percentage isodoses encompassing grade 2 radiological RIP were between 80-85% and mean doses were between 45-48Gy. However for grade 3/4 RIP corresponding values were 90-95% and 50-54Gy. \u0000Conclusion: Incidence of ≥Grade 2 RIP with conformal RT was 16.5%. V20 alone may not be a sufficient predictor for RIP and one should consider conformal RT planning to restrict even higher isodoses beyond the PTV.","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70318483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Extra-Adrenal Paravertebral Thoracic Myelolipoma","authors":"J. Moon, Joungho Han, C. Yi, Y. Choi","doi":"10.6058/JLC.2012.11.2.105","DOIUrl":"https://doi.org/10.6058/JLC.2012.11.2.105","url":null,"abstract":"Extra-adrenal myelolipoma is a rare benign tumor which can occur in the abdomen, thorax, or even in the face. We present a case of 58-year-old woman patient with thoracic myelolipoma, which has manifested as three paravertebral masses at the level of T9 and T10. The computed tomography scan showed heterogenous enhancing masses, which contained fat component. She underwent video-assisted thoracoscopic surgery, and the pathologic examination revealed adipose tissue with many hematopoietic cells, consistent with myelolipoma. (J Lung Cancer 2012;11(2):105�� 107)","PeriodicalId":90901,"journal":{"name":"Journal of lung cancer","volume":"11 1","pages":"105-107"},"PeriodicalIF":0.0,"publicationDate":"2012-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.6058/JLC.2012.11.2.105","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71162033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}